OOIR: Observatory of International Research

Papers

(The H4-Index of Multiple Sclerosis Journal is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: No	94
Progression independent of relapse activity in multiple sclerosis: Time to account for cognitive decline	80
Sars-CoV2 infection in pregnant women with multiple sclerosis	77
Reply to letter to the editor: Olfactory threshold as a biomarker of disease activity	71
Cortical ischemic lesions from atrial myxoma as a mimic of disease activity in an RRMS antiCD20-treated patient	61
All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: Yes	58
Therapy challenges for NMOSD in a patient with HIV	55
Characterizing financial toxicity among people living with neuromyelitis optica spectrum disorder	54
Neurophysiological MEG markers of cognitive impairment and performance validity in multiple sclerosis	54
Severe course of tick-borne encephalitis (TBE) in a patient with relapsing multiple sclerosis (MS) treated with ocrelizumab	44
Erratum to “Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis” Multiple Sclerosis Journal; 2024: 30(8); 1086–1088. DOI: 10.1177/13524585241260564.	42
GM-CSF is a marker of compartmentalised intrathecal inflammation in multiple sclerosis	41
An interdisciplinary approach is necessary in the treatment of cognitive decline in MS: No	40
Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Commentary	38
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO	37
The MoXFo initiative – study design: Considerations related to study design and methodology in exercise research for people with multiple sclerosis	37
Time to move past typical syndromes in the diagnosis of multiple sclerosis	37
Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentary	36
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions	35
Decentralised clinical trials in multiple sclerosis research	35
Paramagnetic rim lesions predict greater long-term relapse rates and clinical progression over 10 years	34
Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: A case series	32
Cerebrospinal fluid–related tissue damage in multiple sclerosis patients with iron rim lesions	32
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial	31
Double-negative neuromyelitis optica spectrum disorder	31

Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity	31
Productivity loss among people with early multiple sclerosis: A Canadian study	29
Dietary habits and advanced imaging/laboratory markers in multiple sclerosis: An exploratory cross-sectional study	29
Thematic analysis of multiple sclerosis research by enhanced strategic diagram	29